American Society of Clinical Oncology

SHERPA: White

People

  1. Solit
    Solit
  2. Drilon
    Drilon
  3. Schram
    Schram
  4. Berger
    Berger
  5. Arcila
    Arcila
  6. Aghajanian
    Aghajanian
  7. Iasonos
    Iasonos
  8. Grisham
    Grisham
  9. Ladanyi
    Ladanyi
  10. Rosen
    Rosen

Groups

  1. Department of Medicine (122)
  2. Early Drug Development Service (122)
  3. Solid Tumor Oncology Division (122)
  4. GSK Faculty (58)
  5. Human Oncology and Pathogenesis Program (56)
  6. Gynecologic Medicine Service (50)
  7. Genitourinary Oncology Service (43)
  8. Thoracic Oncology (41)
  9. Epidemiology and Biostatistics (39)
  10. Gastrointestinal Oncology Service (28)
Search Within
  1. "Early Drug Development Service"
Formats
  1. Meeting Abstract (94)
  2. Journal Article (28)
Groups
  1. Department of Medicine (122)
  2. Early Drug Development Service (122)
  3. Solid Tumor Oncology Division (122)
  4. GSK Faculty (58)
  5. Human Oncology and Pathogenesis Program (56)
  6. Gynecologic Medicine Service (50)

More Groups

People
  1. David Hyman (93)
  2. Michael Berger (38)
  3. David Solit (32)
  4. Alexander Drilon (31)
  5. Alison Schram (31)
  6. Maria Arcila (21)

More People

Years
  1. 2023 (8)
  2. 2022 (10)
  3. 2021 (8)
  4. 2020 (6)
  5. 2019 (17)
  6. 2018 (13)

More Years

Publications
  1. Journal of Clinical Oncology (109)
  2. JCO Precision Oncology (13)

Results (122)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma
    Journal Article

    Mandelker, D.; Marra, A.; Zheng-Lin, B.; Selenica, P.; Blanco-Heredia, J.; Zhu, Y.; Gazzo, A.; Wong, D.; Yelskaya, Z.; Rai, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors
    Meeting Abstract

    McKean, M.; Spira, A. I.; Rosen, E.; Subbiah, V.; Moreno, V.; Gambardella, V.; Vieito, M.; Saavedra, O.; Cousin, S.; Cassier, P. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, Ciara M.; Keohan, M. L.; Meyers, P. A.; Cohen, S. M.; Hensley, M. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors
    Meeting Abstract

    Borad, M. J.; Schram, A. M.; Kim, R. D.; Kamath, S. D.; Sahai, V.; Dotan, E.; Kelley, R. K.; Ponz-Sarvise, M.; Oh, D. Y.; Yachnin, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions
    Meeting Abstract

    Chen, M. F.; Yang, S. R.; Tao, J.; Desilets, A.; Rosen, E.; Gong, Y.; Mullaney, K. A.; Kris, M. G.; Arcila, M. E.; Donoghue, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository
    Meeting Abstract

    Choudhury, N. J.; Harada, G.; Whiting, K.; Shen, R.; Yang, S. R.; Solit, D. B.; Berger, M. F.; Dinapoli, S.; Abou-Alfa, G. K.; Iyer, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort
    Meeting Abstract

    Repetto, M.; Richards, A. L.; Chen, M. F.; Zhu, Y.; Selenica, P.; Gazzo, A.; Lee, P.; Price, A.; Yang, S. R.; Marra, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer
    Meeting Abstract

    Rosen, E.; Sharma, M.; Berz, D.; Caswell-Jin, J. L.; Spira, A. I.; Fulgar, G. A.; Densel, M.; Rana, N.; Sperry, S.; Warner, D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers
    Meeting Abstract

    Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116)
    Meeting Abstract

    Rosen, E.; Silverman, I. M.; Fontana, E.; Lee, E. K.; Spigel, D. R.; Højgaard, M.; Lheureux, S.; Mettu, N. B.; Carneiro, B. A.; Carter, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save